TEL AVIV, Israel, August 28, 2026, 08:19 (EDT)
- BioLineRx ADSs dropped 20.3% to $2.20 in premarket trade on Friday.
- The company set the price for 1.35 million ADSs along with 2.02 million related warrants.
- The $3.75 million in gross proceeds represents approximately 1.6 quarters of the company’s latest operating cash usage.
BioLineRx stock dropped 20.3% after a new funding deal widened the potential dilution pool, exceeding what the cash raised would indicate. The ADSs changed hands at $2.20 at 08:19 EDT, sliding from Thursday’s $2.76 closing price premarket data.
BioLineRx Ltd. (NASDAQ: BLRX) will issue 1,348,921 ADSs priced at $2.78 apiece. The transaction is expected to raise $3.75 million in gross proceeds prior to expenses company announcement.
The investor is additionally granted warrants for 2,023,382 ADSs. Each warrant has an exercise price of $2.78 and will remain valid for five years.
This amounts to 1.5 new warrants issued per ADS bought. The ratio accounts for the market’s response differing from the announced offering price.
| Financing component | ADS equivalents | Reference value |
|---|---|---|
| ADSs issued | 1,348,921 | $2.78 per unit |
| New warrants issued | 2,023,382 | $2.78 strike price |
| Revised warrants | 277,273 | $2.78 strike price |
| Total gross proceeds | — | $3.75 million |
| March cash holdings | — | $17.4 million |
As of March 31, BioLineRx reported approximately 4.35 million ADS equivalents outstanding. After factoring in the newly issued ADSs and warrants, the total rises to an estimated 7.72 million on a simplified fully diluted basis.
The company has also modified warrants for 277,273 ADSs. The exercise price is lowered to $2.78 and the expiration date is now August 2031.
Factoring in the amended warrants brings the simplified total close to 8.0 million. Outstanding ADS equivalents would account for approximately 54% of that figure, prior to adjustments for additional securities or later amendments.
The funding remains strategically important. As of March 31, BioLineRx reported $17.4 million in cash and deposits and recorded $2.28 million used for operating activities in the quarter first-quarter results.
The gross proceeds represent approximately 22% of the previously reported cash balance. This amount is also equivalent to nearly 1.6 quarters of first-quarter operating cash consumption, prior to deducting fees or factoring in any adjustments to spending.
Management had earlier indicated that its cash reserves would last into the first half of 2027. The funds will be used for research, development, working capital, and general corporate purposes.
The upcoming financial update is set to be released soon. BioLineRx intends to announce its second-quarter results on August 31, which is also the anticipated closing date for the offering.
Risks: The deal is still pending closing requirements. Exercising warrants may bring in extra cash but increase dilution, and the clinical pipeline faces ongoing trial, regulatory, and funding risks.
Related articles: Biotechnology
